CUAS

🧬 Interested in pharma, biotech and medical device news? Visit PharmaDeviceNews.com →

Business news, market intelligence, and global industry analysis.

The Latest

Acumen Pharmaceuticals faces strategic reset with $78.6m cash after Alzheimer’s drug failure

NRx Pharmaceuticals moves toward ketamine sales after FDA approval of domestic injectable product

Intellect Design Arena (INTELLECT) near Rs 505: Is the 16% share-price crash justified when AI revenue is growing but profits are not?

Affle 3i to acquire Perion for $420m, but its $228m cash balance changes the deal maths

Space-Eyes’ planned $638 million Nasdaq merger with McKinley Acquisition Corporation puts the defence technology company’s counter-drone systems, future CUAS ticker and ambitious contract-growth strategy under investor scrutiny. Representative image.

Space-Eyes lines up $638m Nasdaq debut via McKinley SPAC as Eric Trump joins as strategic adviser

Space-Eyes agrees $638M Nasdaq listing via McKinley SPAC with Eric Trump advising, on $1M revenue and a $35M pipeline. Can contract conversion close the gap?

byVenkatesh

August 1, 2026

ParaZero Technologies (NASDAQ: PRZO) lands Airobotics deal—turning point for CUAS dominance?

ParaZero wins drone safety deal with Airobotics, signaling rising demand for CUAS tech in autonomous defense drone deployments. Learn what this means.

byPallavi Madhiraju

October 22, 2025

The Latest

Acumen Pharmaceuticals faces strategic reset with $78.6m cash after Alzheimer’s drug failure

NRx Pharmaceuticals moves toward ketamine sales after FDA approval of domestic injectable product

Intellect Design Arena (INTELLECT) near Rs 505: Is the 16% share-price crash justified when AI revenue is growing but profits are not?

Affle 3i to acquire Perion for $420m, but its $228m cash balance changes the deal maths

Space-Eyes lines up $638m Nasdaq debut via McKinley SPAC as Eric Trump joins as strategic adviser

ParaZero Technologies (NASDAQ: PRZO) lands Airobotics deal—turning point for CUAS dominance?

Acumen Pharmaceuticals faces strategic reset with $78.6m cash after Alzheimer’s drug failure

NRx Pharmaceuticals moves toward ketamine sales after FDA approval of domestic injectable product

Intellect Design Arena (INTELLECT) near Rs 505: Is the 16% share-price crash justified when AI revenue is growing but profits are not?

Affle 3i to acquire Perion for $420m, but its $228m cash balance changes the deal maths

SAMILBIO expands Chaeyun skincare with two November launches as K-beauty exports reach $11.1bn

Schneider Electric Infrastructure (SCHNEIDER) shares fall 3.5% despite new factory expansion: What will November results reveal?

Haleon (HLN) near 319p: Does a 15% share-price crash make its valuation attractive after the growth downgrade?

Ethan Allen will split CEO and chair roles, but who gets to choose Farooq Kathwari’s successor?